Document is current

Article History

Received: 12 August 2025

Accepted: 15 September 2025

First Online: 15 October 2025

Declarations

:

: Not applicable.

: The study was initiated and funded harmaEssentia. All authors received funding from PharmaEssentia while undertaking this study. PharmaEssentia commissioned Triducive Partners Limited to facilitate the project and analyze the responses to the consensus statements in line with the Delphi methodology. After engaging Triducive Partners Limited, PharmaEssentia made no contribution to the design and development of the study outside of payment of honoraria. PharmaEssentia took no part in the writing, revision, or editing of the manuscript.

: PB reports research support from Incyte, BMS, CTI (now Sobi), Kartos, Telios, Morphosys, Ajax, Geron, Janssen, Sumitomo, Karyopharm, Ionis, Disc, Blueprint, and Cogent, and honoraria/consulting fees from Incyte, BMS, CTI (now Sobi), GSK, Morphosys (now Novartis), AbbVie, Pharma Essentia, Ionis, Disc, Sumitomo, Karyopharm, Novartis, Geron, Keros, Blueprint, Cogent, Ono, Morphic, Jubilant, and Raythera.MSN reports honoraria/consulting fees from Astrazeneca, Daiichi Sankyo, Gilead sciences, Janssen, Sanofi, AbbVie, Genentech, Bristol Myers Squibb, Pharmacosmos, and Pharmaessentia.JM reports research support from Incyte, BMS, SOBI, Kartos, AbbVie, Morphosys, Ajax, Geron, PharmaEssentia, Italfarmaco Spa, Karyopharm, Disc, and honoraria/consulting fees from Incyte, BMS, SOBI, GSK, Novartis, AbbVie, PharmaEssentia, Italfarmaco Spa, Disc, Sumitomo, Karyopharm, Geron, Keros, Blueprint, and Merck.

: This consensus was not prospectively registered.